Case Report

Successful Treatment of Severe Gastrointestinal Bleeding Secondary to Crohn Disease with Recombinant Factor VIIa

Authors: Eva Girona, MD, PhD, [Joaquín Borrás-Blasco, PharmD, PhD, Venancio Conesa-García, MD, Andrés Navarro-Ruiz, PharmD, Javier Solís, MD, Mariana Fe García-Sepulcre, MD, PhD, Israel Oliver-García, MD, PhD

Abstract

A 58-year-old man diagnosed with ileocolonic Crohn disease was admitted to the emergency room with massive lower gastrointestinal hemorrhage and hypovolemic shock. Treatment was started with methylprednisolone, metronidazole and omeprazole. Within the next 24 hours, he received a total of 9 U of red blood cell concentrate and 2 U of fresh frozen plasma. Because of persistence of bleeding, hypovolemic shock and life-threatening situation, we started therapy with rFVIIa. One dose of 120 μg/kg and another dose of 120 μg/kg three hours after the first dose were administered as compassionate use, with resolution of bleeding in the next 12 hours. On day 4 the patient was stabilized. We performed a total colonoscopy and intubation of the ileocecal valve that showed patchy deep ulcerations in the rectum with bleeding inflammatory pseudopolyps. Acute gastrointestinal bleeding is an unusual complication in Crohn disease. In this case, the use of recombinant activated factor VIIa controlled the massive gastrointestinal bleeding secondary to Crohn disease and without clinically significant adverse effect. There are few case reports documenting the use of recombinant activated factor VIIa for this type of off-label indication. Clinical trials should be carried out to define the dosage and dose interval schedule of rFVIIa in the treatment of uncontrolled massive gastrointestinal bleeding secondary to Crohn disease.


Key Points


* Acute gastrointestinal bleeding is an unusual complication in Crohn disease.The use of recombinant activated factor VIIa controls the massive gastrointestinal bleeding secondary to Crohn disease and without clinically significant adverse effect.


* There are few case reports documenting the use of recombinant activated factor VIIa for this type of off-label indication.


* Clinical trials should be carried out to define the dosage and dose interval schedule of rFVIIa in the treatment of uncontrolled massive gastrointestinal bleeding secondary to Crohn disease.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Robert JR, Sachar DB, Greenstein AJ, et al. Severe gastrointestinal hemorrhage in Crohn's disease. Ann Surg 1991;213:207–211.
 
2. Driver CP, Anderson DN, Keenan RA, et al. Massive intestinal bleeding in association with Crohn's disease. J R Coll Surg Edinb 1996;41:152–154.
 
3. Belaiche J, Louis E, D’Haens G, et al. Acute lower gastrointestinal bleeding in Crohn's disease: characteristics of a unique series of 34 patients. Am J Gastroenterol 1999;94:2177–2181.
 
4. Veroux M, Angriman I, Ruffolo C, et al. Severe gastrointestinal bleeding in Crohn's disease. Ann Ital Chir 2003;74:213–215.
 
5. Keuchel M, Hagenmuller F. Small bowel endoscopy. Endoscopy 2005;37:122–132.
 
6. Vlot AJ, Ton E, Mackaay AJC, et al. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 2000;108:421–423.
 
7. Ejlersen E, Melsen T, Ingerslev J, et al. Recombinant activated factor VII (rFVIIa) acutely normalized prothrombin time in patients with cirrhosis during bleeding from esophageal varices. Scand J Gastroenterol 2001;36:1081–1085.
 
8. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2004;2:78–84.
 
9. Jurlander B, Thim L, Klausen NK, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001;27:373–384.
 
10. Lisman T, Adelmeijer J, Heijnen HF, et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factorindependent fibrin generation. Blood 2004;103:1720–1727.
 
11. Conesa V, Navarro-Ruiz A, Borrás-Blasco J, et al. Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report. Int J Hematol 2005;81:75–76.
 
12. Borrás-Blasco J, Conesa-Garcia V, Navarro-Ruiz A, et al. Use of recombinant factor VIIa for life-threatening bleeding in a patient with severe necrotizing pancreatitis. Pancreas 2005;31:292–294.
 
13. Lam MS, Sims-McCallum RP. Recombinant factor VIIa in the treatment of non-hemophiliac bleeding. Ann Pharmacother 2005;39:885–891.
 
14. White B, McHale J, Ravi N, et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999:107;677–678.
 
15. O’Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293–298.
 
16. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201–205.
 
17. Goodnough LT, Hewitt PE, Silliman CC. Transfusion medicine: joint ASH and AABB educational session. Am Soc Hematol Educ Program 2004;457–472.
 
18. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomised, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8–15.
 
19. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000;26:385–391.